Cancer-specific T cells are required for effective anti-cancer immunity and have a central
role in cancer immunotherapy. However, emerging evidence suggests that only a small …

T cells engineered with chimeric antigen receptors (CARs) have revolutionized the field of
cell therapy and changed the paradigm of treatment for many patients with relapsed or …

Background & Aims No adjuvant therapy has been shown to extend the survival of patients
with hepatocellular carcinoma (HCC) receiving curative treatment. We investigated whether …

The magnesium transporter 1 (MAGT1) is a critical regulator of basal intracellular free
magnesium (Mg2+) concentrations. Individuals with genetic deficiencies in MAGT1 have …

Abstract Poliovirus receptor (PVR, CD155) has recently been gaining scientific interest as a
therapeutic target in the field of tumor immunology due to its prominent endogenous and …

A couple of molecular-targeting medications, such as Lenvatinib, are available for the
treatment of hepatocellular carcinoma (HCC) in addition to Sorafenib in an advanced stage …

Hepatocellular carcinoma (HCC) is a highly heterogeneous malignancy with high incidence,
recurrence, and metastasis rates. The emergence of immunotherapy has improved the …

Introduction: Cytokine-induced killer (CIK) cells are heterogeneous ex vivo-expanded T
lymphocytes with mixed T-NK phenotype and endowed with a wide MHC-unrestricted …

Recent development of methods to discover and engineer therapeutic T‐cell receptors
(TCRs) or antibody mimics of TCRs, and to understand their immunology and …

Cytokine‐induced killer (CIK) cells represent an exceptional T‐cell population uniting a T
cell and natural killer cell‐like phenotype in their terminally differentiated CD3+ CD56+ …